Odycin

Acute bacterial sinusitis, acute aggravation of chronic bronchitis, community-acquired pneumonia, uncomplicated and complicated skin and skin structure infections, complicated intra-abdominal infections, and pelvic inflammatory disease are among the conditions for which moxifloxacin is prescribed.

Pharmaceutical Name

Pharmacology

Moxifloxacin belongs to the fluoroquinolone class of antibacterial drugs, and it is a 4th generation synthetic broad spectrum antibacterial medication. It works against a wide spectrum of bacteria, including Mycoplasma pneumoniae, that are gram-positive, gram-negative, anaerobic, and atypical. Topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, and repair, are inhibited.

Dosage & Administration

Acute bacterial sinusitis: 400 mg once daily 7-10 days.
Acute bacterial exacerbation of chronic bronchitis: 400 mg once daily 5-10 days.
Community-acquired pneumonia: 400 mg once daily 7-14 days.
Uncomplicated skin and skin structure infections: 400 mg once daily 7 days.
Complicated skin and skin structure infections: 400 mg once daily 7-21 days.
Complicated intra-abdominal infections: 400 mg once daily 5-14 days.
Pelvic inflammatory disease: 400 mg once daily 14 days.

Interaction

Moxifloxacin Hydrochloride ophthalmic solution has not been subjected to drug-drug interaction studies. Moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, according to in vitro studies, indicating that it is unlikely to affect the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.

Contraindications

Moxifloxacin Patients with a history of hypersensitivity to Moxifloxacin, other quinolones, or any of the components in this medication should not use the hydrochloride ophthalmic solution.

Side Effects

Conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing were the most commonly reported ocular adverse events. Approximately 1-6 percent of patients experienced these complications. Fever was one of the non-ocular adverse events reported at a rate of 1-4 percent.

Pregnancy & Lactation

Because no adequate and well-controlled studies in pregnant women have been conducted, Moxifloxacin Hydrochloride ophthalmic solution should only be used during pregnancy if the potential benefit outweighs the risk to the fetus.

Precautions & Warnings

Prolonged use of anti-infectives, like other antibiotics, can lead to the overgrowth of non-susceptible organisms, such as fungi. If superinfection occurs, stop using it and seek alternative treatment. When clinical judgment dictates, the patient should be examined under magnification, such as slit lamp biomicroscopy, and fluorescein staining, if appropriate.

Therapeutic Class

4-Quinolone preparations

Storage Conditions

Keep in a dry place, away from light and heat. Keep out of the reach of children.